资料显示，湖岸生物技术有限公司是一家在开曼群岛注册成立的境外控股母公司,主要由其境内实体子 公司北京依生生物技术有限公司运营。依生生物技术有限公司是一家全球性的生物制药公司,致力于发 现、开发、生产和商业化新一代疫苗和治疗性生物制剂,用于治疗传染病和癌症。 本文源自：金融界 作者：行情君 8月11日，湖岸生物(LSB)盘中上涨2.86%，截至21:55，报0.72美元/股，成交702.0美元，总市值2967.31 万美元。 财务数据显示，截至2025年03月31日，湖岸生物收入总额6.15亿人民币，同比增长7.24%；归母净利 润-9998.25万人民币，同比增长76.93%。 ...

Core Viewpoint - Lakeshore Bio (LSB) shows a positive market response with a 3.03% increase in stock price, reflecting investor confidence in the company's financial performance and growth potential [1]. Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, representing a year-on-year growth of 7.24% [1]. - The company achieved a net profit attributable to shareholders of -99.98 million RMB, which indicates a significant year-on-year increase of 76.93% [1]. Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1]. - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1].

Core Viewpoint - Lakeshore Bio (LSB) shows a positive market performance with a 2.49% increase in stock price, reaching $0.679 per share, and a total market capitalization of $27.9834 million [1] Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a significant increase in net profit attributable to shareholders, amounting to -99.9825 million RMB, which represents a year-on-year growth of 76.93% [1] Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

8月6日，湖岸生物(LSB)盘中上涨6.79%，截至21:36，报0.77美元/股，成交562.0美元，总市值3171.32万 美元。 本文源自：金融界 作者：行情君 资料显示，湖岸生物技术有限公司是一家在开曼群岛注册成立的境外控股母公司,主要由其境内实体子 公司北京依生生物技术有限公司运营。依生生物技术有限公司是一家全球性的生物制药公司,致力于发 现、开发、生产和商业化新一代疫苗和治疗性生物制剂,用于治疗传染病和癌症。 财务数据显示，截至2025年03月31日，湖岸生物收入总额6.15亿人民币，同比增长7.24%；归母净利 润-9998.25万人民币，同比增长76.93%。 ...

Group 1 - The stock price of Lakeshore Biosciences (LSB) increased by 19.17% on August 1, reaching $0.90 per share, with a trading volume of $43,400 and a total market capitalization of $37.09 million [1] - As of September 30, 2024, Lakeshore Biosciences reported total revenue of 372 million RMB, representing a year-on-year growth of 36.2% [1] - The net profit attributable to the parent company was 20.58 million RMB, showing a significant year-on-year increase of 111.79% [1] Group 2 - Lakeshore Biosciences is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

资料显示，湖岸生物技术有限公司是一家在开曼群岛注册成立的境外控股母公司,主要由其境内实体子 公司北京依生生物技术有限公司运营。依生生物技术有限公司是一家全球性的生物制药公司,致力于发 现、开发、生产和商业化新一代疫苗和治疗性生物制剂,用于治疗传染病和癌症。 本文源自：金融界 作者：行情君 7月31日，湖岸生物(LSB)开盘上涨8.58%，截至21:30，报0.82美元/股，成交3380.0美元，总市值3379.44 万美元。 财务数据显示，截至2024年09月30日，湖岸生物收入总额3.72亿人民币，同比增长36.2%；归母净利润 2057.9万人民币，同比增长111.79%。 ...

7月29日，湖岸生物(LSB)盘中上涨4.76%，截至22:05，报0.977美元/股，成交4.78万美元，总市值 4026.07万美元。 资料显示，湖岸生物技术有限公司是一家在开曼群岛注册成立的境外控股母公司,主要由其境内实体子 公司北京依生生物技术有限公司运营。依生生物技术有限公司是一家全球性的生物制药公司,致力于发 现、开发、生产和商业化新一代疫苗和治疗性生物制剂,用于治疗传染病和癌症。 本文源自：金融界 作者：行情君 财务数据显示，截至2024年09月30日，湖岸生物收入总额3.72亿人民币，同比增长36.2%；归母净利润 2057.9万人民币，同比增长111.79%。 ...

7月29日，湖岸生物(LSB)开盘上涨7.24%，截至21:30，报1.0美元/股，成交5099.0美元，总市值4121.27 万美元。 财务数据显示，截至2024年09月30日，湖岸生物收入总额3.72亿人民币，同比增长36.2%；归母净利润 2057.9万人民币，同比增长111.79%。 作者：行情君 资料显示，湖岸生物技术有限公司是一家在开曼群岛注册成立的境外控股母公司,主要由其境内实体子 公司北京依生生物技术有限公司运营。依生生物技术有限公司是一家全球性的生物制药公司,致力于发 现、开发、生产和商业化新一代疫苗和治疗性生物制剂,用于治疗传染病和癌症。 本文源自：金融界 ...

Core Viewpoint - LakeShore Biopharma Co., Ltd has announced a share and warrant purchase agreement with an institutional investor, aiming to raise US$15 million through the issuance of ordinary shares and warrants [1] Company Summary - The company is focused on discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer [1] - The agreement involves the issuance of 16,987,542 ordinary shares at a price of US$0.883 per share and 16,987,542 warrants, each allowing the purchase of one ordinary share at an exercise price of US$1.079 over a 36-month period [1] Financial Details - The total amount raised through this private placement is US$15 million, which is exempt from registration under Regulation S of the Securities Act of 1933 [1] - The closing of the private placement is expected to occur soon after the parties agree to the Purchase Agreement, subject to customary conditions [1]